

CITY COUNCIL RESEARCH DIVISION LEGISLATIVE SUMMARY



Brandon Russell
Research Assistant
(904) 255-5137
BRussell@coj.net

117 West Duval Street
City Hall, Suite 425
Jacksonville, FL 32202

Bill Type and Number: Ordinance 2025-0686

Introducer/Sponsor(s): Council Member Salem

Date of Introduction: September 9, 2025

Committee(s) of Reference: F, NCSPHS

Date of Analysis: September 5, 2025

Type of Action: Authorize the city to join a settlement; approve and authorize the Mayor to execute and deliver Subdivision Settlement Participation forms; request one-cycle emergency passage.

Bill Summary: This bill authorizes the City to join with the State of Florida and other local governmental units as a participant in the State's settlement with Alvogen, Inc., Apotex Corp., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals USA Inc., Indivior Inc., Viatrix Inc., Sun Pharmaceutical Industries, Inc., and Zydus Pharmaceuticals Inc. It approves and authorizes the Mayor to execute and deliver the Subdivision Settlement Participation forms to exercise the City's option to participate in these settlements. The bill requests one-cycle emergency passage.

Background Information: The State of Florida has entered into settlement agreements with Alvogen, Inc., Apotex Corp., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals USA Inc., Indivior Inc., Viatrix Inc., Sun Pharmaceutical Industries, Inc., and Zydus Pharmaceuticals Inc. The City of Jacksonville is a participant in the State of Florida's unified plan (the Florida Plan) for the allocation and use of prospective settlement dollars from opioid related litigation, inclusive of the allocation and use of prospective settlement dollars from the Secondary Manufacturers' Settlements. To receive settlement proceeds, the City is required to execute the Secondary Manufacturers' Combined Subdivision Participation and Release Form. The purpose of this legislation is to authorize the City of Jacksonville's participation through completion of these forms.

Policy Impact Area: Opioid settlements

Fiscal Impact: No cost to the City.

Analyst: Russell